Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations.
Tian GeMarguerite R IrvinAmit PatkiVinodh SrinivasasainagendraYen-Feng LinHemant K TiwariNicole D ArmstrongBarbara BenoitChia-Yen ChenKarmel W ChoiJames J CiminoBrittney H DavisOzan DikilitasBethany EtheridgeYen-Chen Anne FengVivian GainerHailiang HuangGail P JarvikChristopher KachulisEimear E KennyAtlas KhanKrzysztof KirylukLeah KottyanIftikhar J KulloChristoph LangeNiall LennonAaron LeongEdyta MalolepszaAyme D MilesShawn MurphyBahram NamjouRenuka NarayanMark J O'ConnorJennifer A PachecoEmma PerezLaura J Rasmussen-TorvikElisabeth A RosenthalDaniel SchaidMaria StamouMiriam S UdlerWei-Qi WeiScott T WeissMaggie C Y NgJordan W SmollerMatthew S LeboJames B MeigsNita A LimdiElizabeth W KarlsonPublished in: Genome medicine (2022)
By integrating T2D GWAS from multiple populations, we developed and validated a trans-ancestry PRS, and demonstrated its potential as a meaningful index of risk among diverse patients in clinical settings. Our efforts represent the first step towards the implementation of the T2D PRS into routine healthcare.
Keyphrases
- healthcare
- type diabetes
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- quality improvement
- primary care
- genome wide association study
- prognostic factors
- peritoneal dialysis
- insulin resistance
- patient reported outcomes
- glycemic control
- skeletal muscle
- health information
- patient reported